$NUWEJun 26, 2026, 12:00 PMAI processed
Ensysce enrolls first patient in final stage of PF614‑MPAR‑102 trial
AI Summary
Ensysce (ENSC) announced first-patient enrollment in Part 3 (final stage) of its PF614‑MPAR‑102 study evaluating PF614‑MPAR, an opioid engineered with a built‑in chemical “safety switch” to limit additional drug release and protect against oral overdose. The program has FDA Breakthrough Therapy designation and NIDA support; prior data showed maintained therapeutic plasma levels at normal doses and blunted exposure at supratherapeutic doses, and Part 3 will test the protective profile across a broader range of dosing scenarios.
Positives
- First patient enrolled in Part 3 (final stage) of PF614‑MPAR‑102 — a clear clinical milestone
- PF614‑MPAR has FDA Breakthrough Therapy designation
- Part 3 is supported by NIDA funding, indicating external validation and support
Negatives
- PF614‑MPAR is investigational and not approved; clinical success is not assured
- Current announcement is enrollment only — efficacy/safety readouts from Part 3 are still pending
- Company highlights general operational and funding risks that could affect program progress